{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:02Z","timestamp":1790690762317,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100225","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:27:56Z","timestamp":1774610876000},"page":"100225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life with linvoseltamab treatment for relapsed\/refractory multiple myeloma in LINKER-MM1"],"prefix":"10.1016","volume":"3","author":[{"given":"James E.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"DeVeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1286-7778","authenticated-orcid":false,"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2026.100225_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clml.2023.03.005","article-title":"Impact of disease progression, line of therapy, and response on health-related quality of life in multiple myeloma: a systematic literature review","volume":"23","author":"Fonseca","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.bneo.2026.100225_bib2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","article-title":"Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry","volume":"20","author":"Jagannath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.bneo.2026.100225_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clml.2022.11.008","article-title":"Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the Connect MM Disease Registry","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100225_bib6","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100225_bib7","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jval.2021.06.010","article-title":"Development of the multiple myeloma symptom and impact questionnaire: a new patient-reported outcome instrument to assess symptom and impacts in patients with multiple myeloma","volume":"24","author":"Gries","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.bneo.2026.100225_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bneo.2026.100225_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100225_bib12","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.bneo.2026.100225_bib15","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2026.100225_bib19","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses","volume":"26","author":"Lee","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.bneo.2026.100225_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bjh.19346","article-title":"Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3","volume":"204","author":"Mohty","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100225_bib24","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.bneo.2026.100225_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","article-title":"Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life","volume":"104","author":"Stead","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100225_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.bneo.2026.100225_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100225_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bneo.2026.100225_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.bneo.2026.100225_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2026.100225_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2026.100225_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.17887","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study","volume":"196","author":"Larocca","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100225_bib34","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100225_bib35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100225_bib36","author":"Scott"},{"key":"10.1016\/j.bneo.2026.100225_bib37","series-title":"Self-Reported Population Health: An International Perspective based on EQ-5D","first-page":"19","article-title":"Population Norms for the EQ-5D","author":"Szende","year":"2014"},{"issue":"14","key":"10.1016\/j.bneo.2026.100225_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35927","article-title":"Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"131","author":"Schinke","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100225_bib39","article-title":"Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice","volume":"5","author":"Ludwig","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"6","key":"10.1016\/j.bneo.2026.100225_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130023","article-title":"Fatigue as a driver of overall quality of life in cancer patients","volume":"10","author":"McCabe","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bneo.2026.100225_bib41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.bneo.2026.100225_bib42","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/s12885-021-08453-9","article-title":"Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study","volume":"21","author":"Tremblay","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:18Z","timestamp":1790687838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000361"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100225","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life with linvoseltamab treatment for relapsed\/refractory multiple myeloma in LINKER-MM1","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100225"}}